57 results on '"Attard P"'
Search Results
2. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
3. Complex patterns of ETS gene alteration arise during cancer development in the human prostate
4. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo
5. DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation
6. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer
7. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide
8. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
9. Dysregulation of cholesterol metabolism in cancer progression
10. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
11. DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability
12. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells
13. Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
14. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing
15. Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer
16. Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy
17. Nuclear receptor HNF4α performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence
18. Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer
19. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy
20. A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
21. Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12
22. O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer
23. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis
24. Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer
25. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth
26. HDAC inhibition impedes epithelial–mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer
27. The biology of circulating tumor cells
28. Arrestin2 modulates androgen receptor activation
29. DNA damage response and prostate cancer: defects, regulation and therapeutic implications
30. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
31. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals
32. Alternative splicing in cancer: implications for biology and therapy
33. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
34. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2
35. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells
36. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
37. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
38. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
39. Targeting the epigenome for treatment of cancer
40. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
41. The Ron receptor promotes prostate tumor growth in the TRAMP mouse model
42. Revisiting the concept of cancer stem cells in prostate cancer
43. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells
44. Towards novel paradigms for cancer therapy
45. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
46. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models
47. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
48. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo
49. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism
50. Polymorphisms in the p53 pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.